Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NNVC
NNVC logo

NNVC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy NanoViricides, Inc (NNVC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.260
1 Day change
-1.56%
52 Week Range
2.230
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

NanoViricides, Inc (NNVC) is not a strong buy at the moment for a beginner investor with a long-term focus. The lack of significant positive catalysts, weak financial performance, and absence of strong trading signals suggest holding off on investment until clearer growth trends or positive developments emerge.

Technical Analysis

The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 70.182, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its resistance level of 1.167, which could act as a barrier to further price increases.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
7

Positive Catalysts

  • MACD indicates bullish momentum. Historical data suggests a 60% chance of moderate gains in the next month.

Neutral/Negative Catalysts

  • No significant news or event-driven catalysts. Financial performance remains weak with declining EPS and negative net income. No recent insider or hedge fund activity indicating confidence in the stock.

Financial Performance

In Q2 2026, revenue remained at 0 with no YoY growth. Net income improved slightly by 9.53% YoY but remains negative at -2,220,719. EPS dropped by 21.43% YoY to -0.11, indicating continued financial struggles.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Wall Street analysts forecast NNVC stock price to rise
1 Analyst Rating
Wall Street analysts forecast NNVC stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.280
sliders
Low
6
Averages
6
High
6
Current: 1.280
sliders
Low
6
Averages
6
High
6
Alliance Global
James Molloy
initiated
$6
AI Analysis
2025-12-16
Reason
Alliance Global
James Molloy
Price Target
$6
AI Analysis
2025-12-16
initiated
Reason
Alliance Global analyst James Molloy initiated coverage of NanoViricides with a Buy rating and $6 price target. NanoViricides is a nano-pharmaceutical company that specializes in creating novel treatments for viral infections, the analyst tells investors in a research note. The firm believes the opportunity for the company "could be significant" should NV-387 show positive data in the planned Phase 2 trials.

People Also Watch